AMEX · SER
Serina Therapeutics, Inc.
Healthcare · Biotechnology
$1.65▼ 6.25% ($0.11)at close
As of 4:00 PM ET
Market cap
$24.75M
P/E
N/M
EPS (TTM)
-$1.29
Next earnings
Nov 18, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need current revenue and shares outstanding to build the revenue-driven FCFF model.
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
Data notes
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $1.65 · Price Oct 23, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 68.09% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow declined 35.46% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Revenue declined 100% — this read reverses if that trend stabilizes. Free cash flow fell 35.46% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Return analysis
Company profile
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain.
Market multiples
Stock splits
Every 250 shares became 7
Every 15 shares became 16
Every 10 shares became 11
Every 4 shares became 5
Every 1 shares became 4
Profitability & growth
Analyst consensus
2
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 18, 2026
Q3 FY26 · EPS est -$0.34 · Revenue est —
Same quarter, year over year
FY26 YTD n/mEach cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined -$1.13 vs -$1.15 · 1 of 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- -$1.91
- n/m
- FY24
- -$3.01
- —
n/m: last year’s figure was zero, a loss or too small to compare against
Q2 FY26
Reported Aug 13, 2026 · Latest
HoverTap a cell to inspect
Actual
-$0.55
Estimate
-$0.47
Year over year
n/m
Vs prior quarter
n/m
Institutional Sentiment
Serina Therapeutics, Inc. · SER
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.